ATLANTA, July 7 GA-GeoVax-AIDS
ATLANTA, July 7 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc.
(OTC Bulletin Board: GOVX), an Atlanta based, publicly traded
biopharmaceutical company specializing in the prevention and treatment of
infectious diseases, today provided an operational update on the company's
progress towards entering Phase 2 preventative human clinical trial testing
and plans to proceed into therapeutic human trials with its AIDS vaccine. Five
successful human trials evaluating GeoVax AIDS vaccines have previously been
reported.
Planned Phase 2 Human Clinical Trial for Prevention of AIDS
The Company's Phase 2 trial, conducted by the U.S. National Institutes of
Health (NIH) supported HIV Vaccine Trials Network (HVTN), will involve 225
healthy volunteers from the United States and South America, and will further
evaluate the safety and immunogenicity of the GeoVax preventative vaccine
(vaccine administered prior to infection with the HIV virus). In Phase 1
trials, both 1/10th dose and full dose of the GeoVax vaccine elicited anti-HIV
T-cells, whereas the full dose was required to elicit good frequencies of
antibody to the HIV Envelope glycoprotein. The larger Phase 2 human trial will
broaden the base of safety and immunogenicity data for the full dose of the
GeoVax AIDS vaccine with a view to protecting recipients from developing AIDS
should they be exposed to the virus. The planned Phase 2 human clinical trial
is currently scheduled to start early this fall, subject to FDA approval.
Preclinical Data for Use of Vaccine Technology as an AIDS Therapeutic
Human Clinical Trials in Planning Stages
GeoVax also announced summary data from a pilot study on therapeutic
vaccination in simian immunodeficiency virus (SIV) infected non-human primates
with the SIV prototype for the GeoVax AIDS vaccine. In this small pilot study,
conducted by Dr. Amara at Emory University, two non-human primates were
infected with SIV. At 12 weeks post SIV infection, conventional anti-viral
drug therapy was given to the primates to reduce the viral RNA infection
levels to very low levels creating a non progressor status for the primate.
Then the SIV prototype vaccine for the GeoVax AIDS vaccine was administered.
Six weeks following the final vaccination, anti-viral drug treatment was
stopped and the animals were monitored to determine whether the vaccine could
control the SIV infection during the absence of the drugs.
The outstanding results from the study revealed the vaccine controlling
the infection in the absence of drugs. In one primate, the reduction in viral
levels over pre-drug treatment and vaccination levels was 1000 times. In the
other, the reductions in viral levels were 100 times. The excellent control of
the virus infection in the absence of drug treatment was associated with the
vaccine raising the types of CD4 and CD8 T cells that are found in the rare
individuals who spontaneously control their HIV infections.
Based on these excellent results, planning for a therapeutic trial in
infected and drug treated humans has been initiated. The intent of therapeutic
vaccination is for the vaccine to "control" HIV virus levels in infected
individuals to very low levels thus blocking the development of AIDS.
Successful therapeutic AIDS vaccination programs with GeoVax vaccines would
lead to reduction in the use of costly anti-HIV medications and their often
harmful side effects.
Dr. Harriet Robinson, GeoVax Co-founder and Senior V.P. of Research and
Development, commented, "I had not anticipated the extent of vaccine control
that was achieved in the already infected non-human primates. These are highly
promising results that need to be extended into infected humans to see if the
vaccine can be used to reduce the need for taking drugs. The results also
warrant more extended studies in already infected non-human primates to
explore parameters that both limit and enhance the ability for a vaccine to
displace the need for drugs."
Dr. Robert McNally, CEO and President of GeoVax Labs, Inc., emphasized,
"It is noteworthy to mention that the GeoVax AIDS vaccines being tested in the
preclinical therapeutic trial is the same basic vaccine administered in the
Company's human trials testing for a preventative use of the vaccine,
vaccinating people before infection to prevent the development of AIDS should
they become infected. Thus, a "one for two" vaccine could be a breakthrough
solution for the company and the world, saving millions of dollars in
redundant development costs and years of testing time by utilizing safety data
already achieved in Phase 1 preventative human trials. More important, time to
market could be significantly reduced, saving lives much sooner than
otherwise."
Further, GeoVax's management is pleased to report that the company is
currently engaged in negotiations with a NIH sponsored trial network to
administer, conduct and co-sponsor GeoVax's Therapeutic human trial program.
Management expects to receive approval for undertaking formal protocol
development in the near future and will report more detailed plans
accordingly.
"From an operational standpoint, we are very pleased with the overall
progress of the company," stated Dr. Robert McNally. "Progress with ongoing
preventative vaccine trials and now the potential to address therapeutic use
of the vaccine gives GeoVax an expanding role in the fight to control AIDS."
About GeoVax Labs, Inc.
GeoVax Labs, Inc. is a biotechnology company, established to develop,
manufacture, license and commercialize human vaccines for diseases caused by
HIV-1 (Human Immunodeficiency Virus) and other infectious agents. GeoVax's
AIDS vaccine technology is the subject of 20 issued or filed patent
applications. GeoVax AIDS vaccines are designed for use in uninfected people
to prevent Acquired Immunodeficiency Disease (AIDS), caused by the virus known
as HIV-1, should the person ever become infected. GeoVax AIDS vaccines also
may be effective as therapeutics, treatment of people already infected with
AIDS virus.
GeoVax's core AIDS vaccine technologies were developed by Dr. Harriet
Robinson, Senior V.P. of Research and Development, through a collaboration of
colleagues at Emory University's Vaccine Center, the National Institutes of
Health (NIH), The Centers for Disease Control and Prevention (CDC) and GeoVax.
GeoVax AIDS vaccines have moved forward in human clinical trials conducted
by the HIV Vaccine Trials Network (HVTN) based in Seattle, Washington. The
HVTN, funded through a cooperative agreement with the National Institutes of
Health (NIH), is the largest worldwide clinical trials program dedicated to
the development and testing of AIDS vaccines. Preclinical work enabling
evaluation of GeoVax DNA and MVA vaccines was funded and supported by NIAID,
which provided additional support to GeoVax AIDS vaccine development program
with a $15 million IPCAVD grant awarded in late 2007.
Safe Harbor Statement: All statements in this news release, not statements
of historical fact, are forward-looking statements. These statements are based
on expectations and assumptions on the date of this press release and are
subject to numerous risks and uncertainties which could cause actual results
to differ materially from those described in the forward-looking statements.
Risks and uncertainties include, but are not limited to, whether: GeoVax can
develop and manufacture these vaccines with the desired characteristics in a
timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines
will effectively prevent AIDS in humans, vaccines will receive regulatory
approvals necessary to be licensed and marketed, GeoVax raises required
capital to complete vaccine development, there is development of competitive
products that may be more effective or easier to use than GeoVax's products,
and other factors over which GeoVax has no control. GeoVax assumes no
obligation to update these forward-looking statements, and does not intend to
do so. Certain matters discussed in this news release are forward-looking
statements involving certain risks and uncertainties including, without
limitation, risks detailed in the Company's Securities and Exchange Commission
filings and reports.
SOURCE GeoVax Labs, Inc.
